Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;32(6):1392-1396.
doi: 10.1111/pai.13519. Epub 2021 May 11.

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema

Henriette Farkas  1 , Avner Reshef  2 , Teresa Caballero  3 , María C Ortega López  4 , Aharon Kessel  5 , Moshe Vardi  6 , James Hao  6 , Werner Aberer  7
Affiliations

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema

Henriette Farkas et al. Pediatr Allergy Immunol. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

HF served as a member of advisory boards for BioCryst, CSL Behring, Octapharma, and Takeda; received grants/honoraria from BioCryst, CSL Behring, Octapharma, Takeda, and Sobi; and served as a clinical trial investigator for BioCryst, CSL Behring, and Takeda. AR received research funding/travel grants/honoraria from BioCryst, Cephalon, CSL Behring, Pharming, Takeda, and Teva and served as an advisor/speaker for CSL Behring and Takeda. TC served as a member of advisory boards for BioCryst, CSL Behring, Novartis, Octapharma, Pharming, and Takeda; served as a member of speaker bureaus for CSL Behring, Merck, Novartis, and Takeda; received grants/honoraria from BioCryst, CSL Behring, Novartis, and Takeda; received funding to attend conferences/educational events from CSL Behring, Novartis, and Takeda; served as a clinical trial/registry investigator for BioCryst, CSL Behring, Novartis, Pharming, and Takeda; and served as a researcher from the IdiPAZ program for promoting research activities. MCOL received travel grants/honoraria from Octapharma and Takeda. AK received travel grants from Pharming and Takeda and received honoraria from CSL Behring and Takeda. MV was a full‐time employee of Takeda at the time of the study and is currently working for Alexion Pharmaceuticals. JH is a full‐time employee of Takeda and holds stock/stock options in Takeda. WA served as a member of advisory boards/speaker bureaus for BioCryst, CSL Behring, Pharming, and Takeda; received research grants from CSL Behring and Takeda; received funding to attend conferences/educational events and donations to departmental fund from Takeda; and is a clinical trial investigator for BioCryst and Takeda.

Figures

FIGURE 1
FIGURE 1
(A) Kaplan‐Meier curves for TOSR after the second icatibant administration. (B) Kaplan‐Meier curves for TOSR after the third icatibant administration. (C) Mean composite symptom score over time after the second icatibant administration. (D) Mean composite symptom score over time after the third icatibant administration. The composite symptom score was calculated as an average of 8 cutaneous/abdominal or 13 laryngeal assessment components. Caregiver administration includes administration by home healthcare provider, patient, parent, legal guardian, or self. HCP, healthcare professional; TOSR, time to onset of symptom relief
See this image and copyright information in PMC

References

    1. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema–the 2017 revision and update. Allergy. 2018;73(8):1575‐1596. - PubMed
    1. Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382(12):1136‐1148. - PubMed
    1. Christiansen SC, Davis DK, Castaldo AJ, Zuraw BL. Pediatric hereditary angioedema: onset, diagnostic delay, and disease severity. Clin Pediatr (Phila). 2016;55(10):935‐942. - PubMed
    1. Farkas H, Martinez‐Saguer I, Bork K, et al. HAWK. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300‐313. - PMC - PubMed
    1. Farkas H, Reshef A, Aberer W, et al. Treatment effect and safety of icatibant in pediatric patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2017;5(6):1671‐1678. - PubMed

Publication types

LinkOut - more resources